Thioridazine-associated immune hemolytic anemia

Area of Science:

• Hematology
• Clinical Pharmacology

Background:

• Immune hemolytic anemia is a serious condition.
• Thioridazine is an antipsychotic medication.

Observation:

• A patient ingested 72 gm of thioridazine over 31 months.
• The patient developed immune hemolytic anemia.

Findings:

• A direct association was observed between thioridazine ingestion and immune hemolytic anemia.
• Drug treatment and hematopoietic response were documented during hospitalization.

Implications:

• This case highlights a potential adverse drug reaction.
• Understanding drug-induced anemia is crucial for patient safety.